Pet Cancer Therapeutics Market forecast to see growth of 10% CAGR from 2017 to 2024 - PowerPoint PPT Presentation


PPT – Pet Cancer Therapeutics Market forecast to see growth of 10% CAGR from 2017 to 2024 PowerPoint presentation | free to download - id: 889b2c-YzBmO


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Pet Cancer Therapeutics Market forecast to see growth of 10% CAGR from 2017 to 2024


Get more details @ The Pet cancer therapeutics sector is a relatively new compared to other pet healthcare sectors. Increasing trend of pet adoption such as dogs and cats owing to improved economic status of people will drive pet cancer therapeutics market size. – PowerPoint PPT presentation

Number of Views:21


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Pet Cancer Therapeutics Market forecast to see growth of 10% CAGR from 2017 to 2024

Pet Cancer Therapeutics Market share to hit
300mn by 2024 Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
Key Insights from Pet Cancer Therapeutics Market
  • Launching of Tanovea-CA1, the FDA approved animal
    drug for treating canine lymphoma is indeed a
    breakthrough in pet cancer therapeutics market.
  • Synonymous with lymphosarcoma, this detrimental
    disease is the most common type of cancer
    affecting dogs.
  • Center for Veterinary Medicine, a subsidiary of
    U.S Food and Administration has recently
    announced a partial approval to this
    groundbreaking anti-cancer drug and depending
    upon the effectiveness, market experts
    anticipates its full approval within few years.
  • A Colorado State University startup, VetDC Inc.,
    is commercially merchandizing these drugs and are
    presently available in the U.S. market by
    licensed veterinarians. Reportedly, TANOVEA-CA1
    is the only effective animal drug available in
    pet cancer therapeutics market for the treatment
    of lymphoma.
  • In veterinary oncology, chemotherapy is the most
    recognized therapeutic model that is extensively
    deployed as one of the most relatively effective
    methodologies of treatment. In fact, in 2016,
    chemotherapy held the largest share of the
    overall pet cancer therapeutics industry.

  • In case of pet cancer treatment, outgrowth of
    cancer cells is tried to limit as much as
    possible but not at the cost of their quality of
  • However, it has been noticed that cats and dogs
    respond to chemotherapy much better than humans,
    which again is pushing pet cancer therapeutics
    market from chemotherapy.
  • Blue Buffalo Foundation and The Petco Foundation
    have entered a partnership to provide a grant of
    USD 750000 to Morris Animal Foundation.
  • Reportedly this grand sum of investment is an
    initiative taken to fund Morris Animal
    Foundations research initiative related to
    osteosarcoma and other additional studies related
    to pet cancer.
  • As per a recent report put forward by Global
    Market Insights, Inc., Pet cancer therapeutics
    market is forecast to exceed a revenue of USD 300
    million by 2024, with a projected CAGR of 10
    over 2017-2024.
  • Some of the prominent biggies in the pet cancer
    therapeutics market include Zoetis, Aratana
    Therapeutics Merial, AB Science, VetDC, Vetivax,
    Karyopharms Verdinexor, and Regeneus.

U.S Pet cancer therapeutics market, by medicine
type, 2013 - 2024 (USD Million)

Table of Content
Chapter 1. Methodology 1.1. Methodology 1.1.1
. Initial data exploration 1.1.2. Statistical
model and forecast 1.1.3. Industry insights and
validation 1.1.4. Market definition forecast
parameters 1.2. Data sources 1.2.1.
Secondary 1.2.2. Primary Chapter 2. Executive
Summary 2.1. Pet cancer therapeutics market
3600 synopsis, 2013 2024 2.1.1. Business
trends 2.1.2. Medicine type trends 2.1.3.
Species trends 2.1.4. Cancer type
trends 2.1.5. Regional trends
Table of Content
Chapter 3. Pet cancer therapeutics Industry
Insights 3.1. Industry segmentation 3.2.
Industry size and forecast, 2013 - 2024 3.3.
Industry impact forces 3.3.1. Growth
drivers Rising number of pets
population Increasing prevalence of
cancer in pets Rising willingness of
pet owners to spend on pet healthcare
Increasing number of new product
development 3.3.2. Industry pitfalls
challenges Side-effects of Pet cancer
therapeutics Dearth of veterinary
oncologist Low out of pocket
expenditure on pet healthcare in developing
Table of Content
3.4. Regulatory landscape 3.4.1. U.S. 3.4.2.
Europe 3.5. Technology landscape 3.5.1. North
America 3.5.2. Europe 3.6. Pipeline
analysis 3.7. Growth potential analysis 3.8.
Porter's analysis 3.9. Competitive landscape,
2016 3.10. PESTEL analysis

Browse Full Market Research Report On Pet
Cancer Therapeutics Market _at_ http//
Request for a Sample of this Research
Report _at_ https//
/detail/2017 https//
Stay In Touch Website Soci
al Media